biostudies-literatureUnknown13(8)Grolleau EThe molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool not only in cancer treatment, but also in the early detection of relapse. However, the clinical interpretation of a ctDNA negative result remains challenging. The characterization of circulating nucleosomes (carrying cell-free DNA) and associated epigenetic modifications (playing a key role in the tumorigenesis of different cancers) may provide useful information for patient management, by supporting the contributive value of ctDNA molecular profiling. Significantly elevated concentrations of H3K27Me3 nucleosomes were found in plasmas at the diagnosis, and during the follow-up, of NSCLC patients, compared to healthy donors (<i>p</i>-value < 0.0001). By combining the H3K27Me3 level and the ctDNA molecular profile, weBiomolecules1255https://www.ebi.ac.uk/biostudies/studies/S-EPMC10452235biostudies-literatureCirculating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling.PMC10452235Couraud SHardat NPayen-Gay LRabeuf RChalabreysse LWozny ASBarthelemy DGeiguer FBalandier JBenzerdjeb NSubtil FCandiracci JHerzog MRaffin MGrolleau ERommelaere GLescuyer GHaon CRodriguez-Lafrasse CfalseCirculating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling.The molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool not only in cancer treatment, but also in the early detection of relapse. However, the clinical interpretation of a ctDNA negative result remains challenging. The characterization of circulating nucleosomes (carrying cell-free DNA) and associated epigenetic modifications (playing a key role in the tumorigenesis of different cancers) may provide useful information for patient management, by supporting the contributive value of ctDNA molecular profiling. Significantly elevated concentrations of H3K27Me3 nucleosomes were found in plasmas at the diagnosis, and during the follow-up, of NSCLC patients, compared to healthy donors (<i>p</i>-value < 0.0001). By combining the H3K27Me3 level and the ctDNA molecular profile, we2023-01-01T00:00:00Z2023 Aug2025-04-19T23:18:36.994Z2025-04-19T23:18:36.994ZS-EPMC104522353762732010.3390/biom13081255